整形外科用再生醫療產品市場 - 成長,趨勢,COVID-19的影響,及預測(2021年~2026年)
市場調查報告書
商品編碼
1034179

整形外科用再生醫療產品市場 - 成長,趨勢,COVID-19的影響,及預測(2021年~2026年)

Orthopedic Regenerative Surgical Products Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

整形外科用再生醫療產品的市場規模,在預測期間內,預計以4.3%的年複合成長率擴大。

COVID-19大流行,由於臨床研究的中斷,選擇性手術的取消,供應鏈的混亂等,預計影響整形外科用再生醫療產品市場。

促進市場成長的要素,有關節炎等的整形外科疾病的盛行率上升和技術進步等。再加上隨著老年人口增加,再生治療必要的整形外科疾病的患者數也增加。可是,有償付條件不良和法規嚴格等要素可能妨礙市場成長。

本報告提供整形外科用再生醫療產品市場相關調查,市場概要,以及各產品,各用途,各終端用戶,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場促進因素
    • 整形外科疾病的盛行率上升
    • 老年人口增加
    • 產品的技術的進步
  • 市場阻礙因素
    • 產品成本高
    • 嚴格法規方案
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 同類移植
    • 細胞為基礎
    • 粘性補充劑
  • 各用途
    • 整形外科的疼痛管理
    • 外傷修復
    • 軟骨和肌腱的修復
    • 關節重建
    • 其他
  • 各終端用戶
    • 醫院
    • 門診病人手術中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Zimmer Biomet
    • Stryker
    • AlloSource
    • Amniox Medical, Inc.
    • Anika Therapeutics, Inc.
    • Smith &Nephew
    • Baxter
    • Vericel Corporation
    • MIMEDX
    • Aptissen SA
    • Arthrex, Inc.

第7章 市場機會及趨勢

簡介目錄
Product Code: 72343

The orthopedic regenerative surgical products market studied is expected to grow with an estimated CAGR of 4.3%, over the forecast period.

The COVID-19 pandemic is expected to have an impact on the orthopedic regenerative surgical products market owing to the disruptions in clinical studies, cancellation of elective procedures, and supply chain disruption. Orthopedic regenerative surgical products suppliers faced several challenges such as travel restrictions, business closures, stay-at-home protocols, and employee illness or quarantines during the pandemic.

A large number of hospitals have canceled or postponed elective surgeries across the world to prevent cross-infection and meet the demands of coronavirus patients. For instance, University Medical Center and Sunrise Health in Las Vegas postponed elective surgeries to save bed capacity in 2020. According to the CovidSurg Collaborative in 2020, orthopedic procedures were canceled most frequently, composing 26% of the total cancelled or postponed surgeries in 2020, which had a short-term negative impact on the market.

Certain factors that are driving the market growth include the rising prevalence of arthritis and other orthopedic conditions and growing technological advancements. According to data published by the Centers for Disease Control and Prevention in 2018, an estimated 54.4 million adults had doctor-diagnosed arthritis, with significantly higher prevalence in women than in men in the United States. In addition, according to the Centers for Disease Control and Prevention estimates about 78.4 million (25.9% of the projected total adult population) adults aged 18 years and older will have doctor-diagnosed arthritis by 2040.

Furthermore, with increase in geriatric population, there is rise in number of people suffering from orthopedic conditions requiring regenerative treatment. Also, utilization of emerging technologies including platelet rich plasma (PRP) therapies, viscosupplements, and stem cells is increased in the healthcare industry. The above-mentioned statistics indicate that the prevalence of arthritis and demand for orthopedic regenerative surgical products are increasing, which may drive market over the forecast period. However, factors such as poor reimbursement scenarios and stringent regulatory scenarios may hamper the growth of the market.

Key Market Trends

Viscosupplements is Expected to Hold a Significant Share Over the Forecast Period

Viscosupplements are the injection of hyaluronic acid which injects into diarthrodial joints, intending to restore the rheological properties of the synovial fluid, thereby producing analgesic, mechanical, chondroprotective, and anti-inflammatory effects. Viscosupplements are usually preferred by healthcare providers to treat osteoarthritis, but then it may also benefit patients with certain other kinds of arthritis, such as rheumatoid arthritis.

An increase in the incidence of knee pain and osteoarthritis is expected to drive the viscosupplements segment growth over the forecast period. According to the Statistics Canada in 2021, approximately 5.9 million adult Canadians had arthritis in 2020. The prevalence of arthritis increases with age and is higher among females.

Furthermore, obesity is another risk factor contributing to orthopedic conditions. According to the World Health Organization in 2021, about 13% of the world's adult population were obese in 2016 and 38.2 million children under the age of 5 years were overweight in 2019. Based on the above-mentioned facts, it is expected that the viscosupplements segment will augment over the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America holds the major market share in the orthopedic regenerative surgical products market and is expected to dominate the overall market, throughout the forecast period owing to the increasing incidences of orthopedic conditions, growing geriatric population, and high adoption of regenerative orthopedics in the region. In the North America region, the United States is slated to be the largest market due to the presence of a large number of orthopedic regenerative surgical products manufacturers and suppliers. In addition, According to United States Census Bureau, there were 54.1 million United States residents 65 years and older in July 2019. Furthermore, high awareness of orthopedic regenerative surgical products and high prevalence of arthritis joint pain with other co-occurring conditions such as diabetes among adults in the United States has led North America to witness tremendous growth in the orthopedic regenerative surgical products market. For instance, severe joint pain is more common among adults with arthritis with other chronic conditions such as heart disease (34.1%), diabetes (40.9%), disability (45.6%), obesity (31.7%), and psychological distress (56.3%).

Furthermore, adoption of mergers and acquisitions and partnerships as a key growth strategy by regional companies is anticipated to further propel market over the forecast period. For instance, on 6 May 2021, MIMEDX Group, Inc. and the Wake Forest Institute for Regenerative Medicine announced a collaborative agreement to advance regenerative science and innovative biologics.

Competitive Landscape

The orthopedic regenerative surgical products market is highly competitive in nature with several players across globe. Companies, like Zimmer Biomet, Stryker, AlloSource, Amniox Medical, Inc., Anika Therapeutics, Inc., Smith & Nephew, Baxter, Vericel Corporation, MIMEDX, and Aptissen S.A, among others, hold the substantial market share in the market studied.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Prevalence of Orthopedic Diseases
    • 4.2.2 Increasing Geriatric Population
    • 4.2.3 Technological Advancements in the Products
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Products
    • 4.3.2 Stringent Regulatory Scenario
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Allograft
    • 5.1.2 Cell-based
    • 5.1.3 Viscosupplements
  • 5.2 By Applications
    • 5.2.1 Orthopedic Pain Management
    • 5.2.2 Trauma Repair
    • 5.2.3 Cartilage and Tendon Repair
    • 5.2.4 Joint Reconstruction
    • 5.2.5 Others
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Zimmer Biomet
    • 6.1.2 Stryker
    • 6.1.3 AlloSource
    • 6.1.4 Amniox Medical, Inc.
    • 6.1.5 Anika Therapeutics, Inc.
    • 6.1.6 Smith & Nephew
    • 6.1.7 Baxter
    • 6.1.8 Vericel Corporation
    • 6.1.9 MIMEDX
    • 6.1.10 Aptissen S.A
    • 6.1.11 Arthrex, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS